| Date: <u>6<sup>th</sup> of J</u> | anuary 2022   |
|----------------------------------|---|
| Your Name:                       | Sarah Badaoui   |
| Manuscript 1                     | itle: The predictive utility of patient-reported outcomes and performance status for survival in metastatic |
| lung cancer p                    | patients treated with chemoimmunotherapy  |
| Manuscript r                     | number (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | Time frame: Since the initialNone  | planning of the work  |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--|------|--|
| 6  | Payment for expert<br>testimony  | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
| 8  | Patents planned, issued or pending   | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

Nil to report

Please place an "X" next to the following statement to indicate your agreement:

\_\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: 03/01/22    | Date: <u>03/01/22</u>   |  |  |  |
|-------------------|---|--|--|--|
| Your Name:        | Adel Shahnam  |  |  |  |
| Manuscript Title  | : The predictive utility of patient-reported outcomes and performance status for survival in metastatic |  |  |  |
| lung cancer patie | nts treated with chemoimmunotherapy   |  |  |  |
| Manuscript num    | ber (if known):   |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   | 1                             | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--|------|--|
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

No conflict of interest

## Please place an "X" next to the following statement to indicate your agreement:

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: <u>27 December 2021</u>                |   |  |  |
|--|---|--|--|
| Your Name:                                   | Ross McKinnon   |  |  |
| Manuscript Ti                                | itle: The predictive utility of patient-reported outcomes and performance |  |  |
| status for surv                              | vival in metastatic lung cancer patients treated with                     |  |  |
| chemoimmun                                   | notherapy_  |  |  |
| Manuscript number (if known): TLCR-21-938-CL |   |  |  |
|  |   |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | xNone  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | Yes  | Professorial Fellowship – Cancer Council South Australia                                  |
| 3 | Royalties or licenses  | _xNone   |   |
| 4 | Consulting fees  | _xNone   |   |

|    | ſ                            |        |   |
|----|------------------------------|--------|---|
|    |                              |        |   |
|    |                              |        |   |
| 5  | Payment or honoraria for     | x None |   |
|    | lectures, presentations,     |        |   |
|    | speakers bureaus,            |        |   |
|    | manuscript writing or        |        |   |
|    | educational events           |        |   |
| 6  |                              |        |   |
| 6  | Payment for expert           | x_None |   |
|    | testimony                    |        |   |
|    |                              |        |   |
| 7  | Support for attending        | x None |   |
|    | meetings and/or travel       |        |   |
|    | <u> </u>                     |        |   |
|    |                              |        |   |
|    |                              |        |   |
|    |                              |        |   |
| 8  | Patents planned, issued or   | xNone  |   |
|    | pending                      |        |   |
|    |                              |        |   |
| 9  | Participation on a Data      | x None |   |
| 9  |                              |        |   |
|    | Safety Monitoring Board or   |        |   |
|    | Advisory Board               |        |   |
| 10 | Leadership or fiduciary role | Yes    | Board Member – Therapeutic Innovation Australia. Not- |
|    | in other board, society,     |        | for-profit.   |
|    | committee or advocacy        |        |   |
|    | group, paid or unpaid        |        |   |
| 11 | Stock or stock options       | x None |   |
|    |                              |        |   |
|    |                              |        |   |
| 12 |                              |        |   |
| 12 | Receipt of equipment,        | _xNone |   |
|    | materials, drugs, medical    |        |   |
|    | writing, gifts or other      |        |   |
|    | services                     |        |   |
| 13 | Other financial or non-      | _xNone |   |
|    | financial interests          |        |   |
|    |                              |        |   |
|    |                              |        |   |

Board Member of Not-for-Profit entity that co-ordinates infrastructure for therapeutic development, funded by Australian Government.

Salary is supported by a Fellowship from philanthropic source – Cancer Council South AUstralia

### Please place an "X" next to the following statement to indicate your agreement:

\_\_\_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### Date: 27/12/2021

#### Your Name: Ahmad Y Abuhelwa

Manuscript Title: The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy Manuscript number (if known): N/A

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None  |   |
| 3 | Royalties or licenses  | None  |   |
| 4 | Consulting fees  | None  |   |

| 5  | Payment or honoraria for lectures, presentations,  | None |
|----|--|------|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |
| 6  | Payment for expert testimony   | None |
| 7  | Support for attending meetings and/or travel   | None |
| 8  | Patents planned, issued or pending   | None |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |
| 11 | Stock or stock options   | None |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |
| 13 | Other financial or non-<br>financial interests   | None |

None

Please place an "X" next to the following statement to indicate your agreement:

\_ X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## Date: 16/11/2021

Your Name: Michael Sorich

Manuscript Title: The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy Manuscript number (if known): N/A

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | Cancer Council of South<br>Australia  | Institution   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).<br>Royalties or licenses  | Pfizer<br>None  | Grant unrelated to current work.  |
| 4 | Consulting fees  | None  |   |
|   |  |   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events<br>Payment for expert | None None |  |
|----|--|-----------|--|
| 0  | testimony  |           |  |
| 7  | Support for attending meetings and/or travel   | None      |  |
| 8  | Patents planned, issued or pending   | None      |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None      |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid                                     | None      |  |
| 11 | Stock or stock options   | None      |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | None      |  |
| 13 | Other financial or non-<br>financial interests   | None      |  |

Dr. Sorich reports grants from Cancer Council of South Australia, during the conduct of the study; grants from Pfizer, outside the submitted work

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

#### Date: 16/11/2021

#### Your Name: Ashley Hopkins

Manuscript Title: The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy Manuscript number (if known): N/A

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)                       |  |  |  |  |
|---|--|--|---|--|--|--|--|
|   | Time frame: Since the initial planning of the work   |  |   |  |  |  |  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | National Health and<br>Medical Research<br>Council   | A.M.H is supported by an Investigator Grant<br>from Australia's National Health and Medical<br>Research Council |  |  |  |  |
|   | Time frame: past 36 months   |  |   |  |  |  |  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |  |  |  |  |
| 3 | Royalties or licenses  | None   |   |  |  |  |  |
| 4 | Consulting fees  | None   |   |  |  |  |  |

|    |  |      | 1 |
|----|--|------|---|
|    |  |      |   |
|    |  |      |   |
| 5  | Payment or honoraria for                           | None |   |
|    | lectures, presentations,                           |      |   |
|    | speakers bureaus,                                  |      |   |
|    | manuscript writing or                              |      |   |
|    | educational events                                 |      |   |
| 6  | Payment for expert                                 | None |   |
|    | testimony  |      |   |
|    |  |      |   |
| 7  | Support for attending                              | None |   |
|    | meetings and/or travel                             |      |   |
|    | ,  |      |   |
|    |  |      |   |
|    |  |      |   |
|    |  |      |   |
| 8  | Patents planned, issued or                         | None |   |
|    | pending  |      |   |
|    |  |      |   |
| 9  | Participation on a Data                            | None |   |
|    | Safety Monitoring Board or                         |      |   |
|    | Advisory Board                                     |      |   |
| 10 | Leadership or fiduciary role                       | None |   |
|    | in other board, society,                           |      |   |
|    | committee or advocacy                              |      |   |
|    | group, paid or unpaid                              |      |   |
| 11 | Stock or stock options                             | None |   |
|    |  |      |   |
|    |  |      |   |
| 12 | Receipt of equipment,<br>materials, drugs, medical | None |   |
|    |  |      |   |
|    | writing, gifts or other                            |      |   |
|    | services   |      |   |
| 13 | Other financial or non-<br>financial interests     | None |   |
|    |  |      |   |
|    |  |      |   |
|    |  |      |   |

A.M.H is supported by an Investigator Grant from Australia's National Health and Medical Research Council.

A.M.H has no other conflicts of interest to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.